Introduction: The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is unknown.
survival (PFS) with ICPi, and overall survival were analyzed.
Results: High (!50%), intermediate (1-49%) , and no (<1%) PD-L1 expression was observed in 8 of 19 (42%), 6 of 19 (32%), 5 of 19 (26%), and 5 of 10 (50%), 1 of 10 (10%), and 4 of 10 (40%) cases in groups A and B, respectively. Two tumors in group A showed high TMB (25%); none were microsatellite instability status-high. Twenty-two patients (group A, n ¼ 12; group B, n ¼ 10) received ICPi. Objective response rate with ICPi was 25% and 33% in groups A and B, respectively (p ¼ 1.0). Median PFS with ICPi was 3.7 months (95% confidence interval [CI]: 1.6-6.6), and 4.1 months (95% CI: 0.1-19.6) in groups A and B, respectively (log-rank test ¼ 0.81, p ¼ 0.37). Neither BRAF mutation type nor PD-L1 expression affected the response probability/PFS. Median overall survival was not reached (95% CI: 13-NR) and comprised 21.1 months (95% CI: 1.8-NR) for patients who were and were not exposed to ICPi, respectively (log-rank test ¼ 5.58, p ¼ 0.018).
Conclusions: BRAF mutant NSCLC is associated with high level of PD-L1 expression, low/intermediate TMB and microsatellite-stable status. ICPi have favorable activity both in BRAF V600E and BRAF non-V600E mutant NSCLC.
Introduction
BRAF is a serine/threonine kinase which lies downstream of RAS and directly activates MEK1/2, resulting in ERK1/2 phosphorylation. Activating mutations in the BRAF gene lead to constitutive kinase activity triggering downstream pathways regulating cancer cell proliferation and survival, and therefore, represent an oncogenic driver. These mutations are detected in 2% to 4% of lung cancer patients, predominantly in the adenocarcinoma histologic subtype without obvious ethnicity or gender predominance. [1] [2] [3] [4] The V600E mutations (V600E amino acid substitution in exon 15) comprise roughly half of these cases, typically resulting in elevated basal activity of serine/threonine kinase. In contrast, non-V600E mutations (distributed in exons 11 and 15) have variable degrees of BRAF kinase activity but may result in MEK activation through transactivation of Raf-1 proto-oncogene, serine/threonine kinase (CRAF). 3, 5 The V600E BRAF mutations are associated with female sex and never-smoking status. 2, 4 Non-V600E mutations are typically found current or former smokers. 2 Although the prognostic implications of BRAF mutation in NSCLC are unclear, several studies have associated BRAF V600E with lower response rates and shorter disease-free survival and overall survival (OS) with platinum-based chemotherapy. 2, 3 These tumors, however, tend to derive larger benefit from BRAF inhibition. 6 In fact, in the V600E BRAF mutant NSCLC, therapy with an anti-BRAF agent is associated with objective response rate (ORR) in the range of 33% to 42% and median progression-free survival (PFS) of 5.5 to 7.3 months. 7, 8 Combining BRAF inhibitors with MEK inhibitors appears to be even more effective strategy with ORR of 63% to 64% and median PFS of 9.7 months. 9, 10 In contrast, the majority of non-V600E BRAF mutations do not respond to BRAF inhibition. 6 However, the paucity of data with regards to efficacy of biologic agents in non-V600E tumors precludes firm conclusions to be drawn. Indeed, some of those mutations (e.g., G596V, BRAF Y472C) might confer sensitivity to anti-BRAF or anti-MEK therapy. 6, 11 The efficacy of immune checkpoint inhibitors (ICPi) in BRAF mutant NSCLC is largely unknown. None of the large clinical trials testing anti-programmed death 1 (PD-1)/anti-programmed death ligand 1 (PD-L1) agents in a nonselected population of advanced NSCLC patients reported on outcomes in this specific subgroup. [12] [13] [14] [15] [16] To the best of our knowledge, no prospective study has been initiated to explore the efficacy of ICPi in BRAF mutant NSCLC either.
PD-L1 expression has recently emerged as an important predictive biomarker for anti-PD-1/anti-PD-L1 agents in advanced NSCLC. 12 Recent studies have shown that high tumor mutational burden (TMB) and microsatellite instability-high status (MSI-H) have a predictive value with ICPi as well. [16] [17] [18] Therefore, further research exploring the efficacy of ICPi in correlation with different molecular parameters predicting its efficacy (e.g., PD-L1 expression, TMB, and MSI) in BRAF mutant NSCLC is warranted.
Here, we report the prevalence of PD-L1 expression along with TMB and MSI status, and clinical outcomes with anti-PD-1 ICPi in a cohort of BRAF mutant advanced NSCLC patients.
Materials and Methods
Patients with histologically confirmed BRAF mutant advanced NSCLC were identified through an internal database of each of the seven participating Israeli cancer centers. Both tumors with V600E mutations and non-V600E mutations in the BRAF gene were included in the analysis. The patients were divided into two groups: BRAF V600E mutant tumors (group A), and non-V600E BRAF mutant tumors (group B).
Baseline demographic, clinical, and pathologic characteristics including PD-L1 expression and BRAF mutation type were collected. In those cases where FoundationOne (Foundation Medicine, Cambridge, Massachusetts) testing was performed, information regarding the TMB and MSI status was collected based on the formal report. ORR with ICPi was the primary endpoint of the analysis. PFS with ICPi and OS were assessed as well.
PD-L1 by immunohistochemistry (IHC) was assessed by the pathology specialist in each of the participating centers using 22C3 PharmDx antibody on the Dako 22C3 PD-L1 IHC platform (Dako, Carpinteria, California) or Ventana's BenchMark XT platform (Ventana Medical Systems, Tucson, Arizona). The validation of PD-L1 IHC analysis based on the 22C3 PharmDx antibody and Ventana's BenchMark XT has been published and therefore has been adopted by the majority of molecular pathology laboratories in Israel. 19 PD-L1 tumor proportion score (TPS), which is the percentage of tumor cells showing partial or complete membrane staining was determined and classified as negative, intermediate, or high (TPS of <1%, 1% to 49%, and !50%, respectively).
Comprehensive genomic profiling using the FoundationOne assay was performed as previously described. 20 Briefly, hybridization capture of exon regions from 315 cancer-related genes and select introns from 28 genes commonly rearranged in cancer was applied to !50 ng of DNA extracted from formalin-fixed paraffin-embedded clinical cancer specimens. These libraries were sequenced to high, uniform median coverage (>500Â) and assessed for base substitutions, short insertions and deletions, copy number alterations, and gene fusions/ rearrangements.
TMB was calculated according to the FoundationOne algorithm as previously described in detail. 21 Briefly, TMB was defined as the number of somatic, coding, base substitutions, insertions, and deletion mutations per megabase (Mb) of genome examined. Synonymous and nonsynonymous alterations were counted; noncoding and germline alterations were not counted. Alterations listed in the Catalogue of Somatic Mutations in Cancer (COSMIC) as known somatic alterations and truncations in tumor suppressor genes were not counted (to limit bias towards genes with functional mutations in cancer). To calculate the TMB per Mb, the total number of mutations counted was divided by the size of the coding region of the targeted territory (w1.1 Mb). TMB results, which were rounded to the nearest integer, were determined as follows: TMB-High corresponded to greater than or equal to 20 mutations per Mb (muts/ Mb); TMB-Intermediate corresponded to 6 to 19 muts/ Mb; TMB-Low corresponded to fewer than or equal to 5 muts/Mb.
MSI was calculated according to the FoundationOne algorithm as previously described in detail. 21 To determine MSI status, 114 intronic homopolymer repeat loci with adequate coverage on the comprehensive genomic profiling panel were analyzed for length variability and compiled into an overall MSI score via principal components analysis. MSI was reported as "MSI-High (MSI-H)", "MSI-Intermediate (MSI-I)", and "MS-Stable (MS-S)".
For patients who had adequate computer tomography (CT)/positron-emission tomography-CT scans for radiological assessment, the images were reviewed by the treating physician. For those with measurable disease, changes in the sum of the longest diameters of target lesions during ICPi therapy were reported and analyzed in correlation with BRAF mutation type and PD-L1 expression using Wilcoxon two-sample tests (for tumor shrinkage/growth as a continuous variable) and Fisher's exact test (for response using Response Evaluation Criteria in Solid Tumors 1.1). 22 ORR, PFS with ICPi (assessed by the treating physician using Response Evaluation Criteria in Solid Tumors 1.1.) and OS with ICPi were assessed and analyzed in correlation with BRAF mutation type and PD-L1 expression. 22 PFS was calculated from the day of treatment initiation until disease progression, death, or start of another systemic treatment; the outcome was censored if a patient was alive without known progression of disease at the time of last follow-up. OS with ICPi was calculated from the day of treatment initiation until death; the outcome was censored if a patient was alive at the time of last followup. Additionally, OS calculated from the date of advanced disease diagnosis was assessed and analyzed according to the BRAF mutation type and whether ICPi therapy was delivered.
Fisher's exact and Wilcoxon two-sample tests were used to compare the demographic, clinical, and pathologic characteristics between groups A and B, and between patients who received ICPi and those who did not. Median PFS and OS were estimated using the KaplanMeier method, and curves were compared by the logrank test. All reported p values are based on two-sided hypothesis tests. The statistical analysis was performed using SAS, v. 9.4 (SAS, Cary, North Carolina). 23 The study was conducted in accordance with the principles of good clinical practice, and institutional review board approval was obtained before reviewing the patients' charts and electronic medical records.
Results

Demographics and Baseline Clinical Characteristics
Thirty-nine cases with histologically confirmed BRAF mutant advanced NSCLC treated in one of the seven Israeli cancer centers between June 2013 and December 2017 were identified. The cohort included 21 (54%) patients with BRAF V600E mutation (group A) and 18 (46%) patients with BRAF non-V600E mutation (group B).
Baseline demographic and clinical characteristics of the cohort are presented in Table 1 . There were no differences between groups A and B except for smoking status (p ¼ 0.02). A similar proportion of patients in each group was exposed to ICPi. Moreover, a similar proportion of patients in each group received ICPi as a first, second and third line of treatment (p ¼ 0.18).
Of the 39 patients, 56% received ICPi (Table 1) . Patients not treated with ICPi had higher Eastern Cooperative Oncology Group (ECOG) performance status (PS) score at the time of presentation (p ¼ 0.002). Patients who were treated with ICPi tended to receive more lines of systemic treatment (p ¼ 0.02). Additionally, more patients who did not receive ICPi did not get any systemic treatment at all (p ¼ 0.059).
Results of Molecular Profiling, PD-L1 Staining, TMB, and MSI Assessment
Tumors were profiled by commercially available nextgeneration sequencing assays using FoundationOne (n ¼ 18, 46%), Oncomine Comprehensive Assay (Thermo Fisher Scientific, Waltham, Massachusetts) (n ¼ 4, 10%), and PGDx (Carel Industries S.p.A., Padova, Italy) (n ¼ 1, 3%). Liquid biopsy was performed in five patients (Guardant360 (Guardant Health, Redwood City, California), n ¼ 4 [10%]; FoundationAct, n ¼ 1 [3%]). Eleven cases (28%) were diagnosed by hot-spot panel testing. PD-L1 was assessed in 29 (74%) patients. TMB and MSI using the FoundationOne algorithm were assessed in 11 (28%) and 12 (31%) patients, respectively.
Of the 29 tumors tested, a high level of PD-L1 expression (TPS ! 50%) was observed in 42% and 50% of cases in groups A and B, respectively ( Table 2) . Distribution of PD-L1 expression in groups A and B is presented in Table 2 . The differences in PD-L1 distribution between the groups were statistically significant (p ¼ 0.05). Of the 11 tumors tested, TMB was only high (> 20 muts/Mb) in two cases in group A (25%, Table 2 ). Median TMB comprised 5 muts/Mb (range, 1 to 42 muts/Mb) and 11 muts/Mb (range, 7 to 14 muts/Mb) in groups A and B, respectively. All the tested tumors (8 tumors in group A and 4 tumors in group B) were MSStable. No significant differences between the study groups in terms of TMB and MSI status were seen.
More patients treated with ICPi as compared to those who did not receive ICPi had a high level of PD-L1 expression (p ¼ 0.056) ( Table 2) . Additionally, both patients with high TMB received ICPi, whereas none of a Non-V600E BRAF mutations: N581S (n-3), G469A (n-2), G469V (n-3), G466A (n-1), G596R (n-1), K601N (n-1), R462K (n-1), F595L (n-1), KMT2E (n-1), L597P (n-1), p.I592M/ c.1776A>G (n-1), V111L (n-1), and A598_T599insT (n-1). ICPi, immune checkpoint inhibitors; NA, not applicable; MSI, microsatellite instability; MS-S/MSI-I/MSI-H, microsatellite instability status stable/intermediate/high; muts, mutations; PD-L1, programmed-death ligand 1; pos, positive; TMB, tumor mutational burden; TPS, tumor proportion score.
the patients in the group without ICPi exposure had high TMB (p ¼ 0.34) ( Table 2) .
Outcomes With ICPi
Response. Twenty-two patients (57% of group A, 55% of group B) received ICPi (nivolumab, n ¼ 11; pembrolizumab, n ¼ 10; and atezolizumab, n ¼ 1). Distribution of the treatment lines is presented in Table 1 . In 21 patients who had adequate CT/positron-emission tomographic-CT scans for radiological assessment, the images were reviewed and changes in the sum of the longest diameters of target lesions at best response were assessed. One patient had died soon after the treatment initiation without tumor response evaluation being performed. ICPi therapy was associated with an ORR of 28%. Median tumor shrinkage/growth comprised þ38% (range, -100 to þ260) and -20% (range, -100 to þ150) for groups A and B, respectively (p ¼ 0.30). ORR comprised 25% (3 of 12) and 33% (3 of 9) in groups A and B, respectively (p ¼ 1.0). No correlation was observed between the level of PD-L1 expression and the depth of response either. Median tumor shrinkage/ growth comprised -20% (range, -100 to þ260) and þ55% (range, -30 to þ122) for tumors with PD-L1 ! 50% and PD-L1 0% to 49%, respectively (p ¼ 0.16). ORR comprised 36% (4 of 11) and 14% (1 of 7) for tumors with PD-L1 ! 50% and PD-L1 0% to 49%, respectively (p ¼ 0.59). Of the patients whose tumor shrunk during immunotherapy, 4 received pembrolizumab as a first-line treatment, and 2 were treated with nivolumab as a second-line therapy. Changes in the sum of the longest diameters of target lesions at best response as compared to baseline during ICPi therapy according to the BRAF mutation type and PD-L1 expression level are presented in Figures 1A and 1B Fig. 2D] ).
Co-Expressing Tumors (BRAF V600E and PD-L1 ! 50%)
Eight patients with co-expressing tumors (BRAF V600E and PD-L1 ! 50%) were included in the series. The median age of patients with co-expressing tumors was 64 years old (range, 54 to 87 years); five of eight patients with co-expressing tumors were females; six of eight patients had no smoking exposure; in seven of eight cases the histologic tumor subtype were adenocarcinoma. TMB and MSI were only assessed in one co-expressing tumor; this tumor had low TMB (1 muts/Mb) and MS-Stable status. All patients with co-expressing tumors presented with advanced-stage disease, two of eight patients presented with brain metastases, five of eight had ECOG PS-1, and three of eight had ECOG PS-2 at presentation. Overall, baseline clinical and pathological characteristics of patients with coexpressing tumors were similar to those in group A (Table 1) .
In six of eight patients with co-expressing tumors, ICPi were initiated (first-line, n ¼ 3; second-line, n ¼ 2; third-line, n ¼ 1; pembrolizumab, n ¼ 4; nivolumab, n ¼ 2). In two of six patients major tumor shrinkage was achieved; in three of six the tumors grew, including two cases of hyperprogression (Fig. 1) . PFS with ICPi comprised 1.6, 1.7, 2.1, 4þ, 5.3, and 6.6 months. All four patients who were treated with dabrafenib þ trametinib combination (first-line, n ¼ 2; second-line, n ¼ 1; thirdline, n ¼ 1) showed a tumor shrinkage. PFS with dabrafenib þ trametinib combination comprised 1.8þ, 2.5þ, 3þ, and 9.2 months.
OS Since the Diagnosis of Advanced Disease
With median follow-up of 11.2 months (IQR ¼ 5.9 to 21.1) since the diagnosis of advanced disease 14 of 37 (38%) patients died (35% and 41% in groups A and B, respectively). After excluding patients with early-stage disease (one patient in each group), median OS was not reached in group A (95% CI: 6.7-NR), and comprised 33.9 months (95% CI: 4.6-NR) in group B (log-rank test ¼ 0.11, p ¼ 0.74) (Fig. 3A) .
At the time of the analysis, 5 of 22 (23%) patients and of 15 (60%) patients who were and were not exposed to ICPi, respectively, had died. In patients who were treated with ICPi, median OS was not reached (95% CI: 13-NR); in patients who were not exposed to ICPi, median OS comprised 21.1 months (95% CI: 1.8-NR). The difference was statistically significant (log-rank test ¼ 5.58, p ¼ 0.018) (Fig. 3B) .
Discussion
Our series, to the best of our knowledge, is the first report in the literature on the prevalence of PD-L1 expression and outcomes with ICPi in BRAF mutant NSCLC.
According to our data, presence of a BRAF mutation in NSCLC is associated with higher levels of PD-L1 expression. Specifically, the prevalence of tumors with a high level of PD-L1 expression among BRAF mutant NSCLC varies between 42% and 50%, which is higher compared to the previously reported rate of 28% in the overall population of NSCLC patients. 13 It is uncommon to see a high level of PD-L1 expression in NSCLC harboring an actionable genomic aberration in the EGFR, ALK receptor tyrosine kinase (ALK) or ROS-1 genes. 24 From that point of view, tumors bearing BRAF mutations are similar to MNNG HOS Transforming gene (MET) exon 14 mutant tumors, showing a high level of PD-L1-expression in 46% of cases. 25 Differences in the PD-L1 distribution between the BRAF V600E and non-V600E BRAF mutant tumors were observed. These, however, being statistically significant, are less clinically relevant because the proportion of tumors with a high level of PD-L1 expression is similar between the groups. According to our results, BRAF mutant NSCLCs are not associated with MSI-High status. In our cohort, the median TMB comprised 7 muts/Mb (range, 1 to 42 muts/Mb) and 18% of tumors were associated with TMB of ! 20 muts/Mb -which is in line with the previously reported data for the nonselected population of patients with lung cancer. The role of ICPi in NSCLC harboring a driver mutation is controversial. For instance, tumors harboring an activating mutation in the EGFR gene do not seem to derive a significant benefit from treatment with ICPi. In fact, patients with EGFR mutant advanced NSCLC perform better with chemotherapy as compared to ICPi, and ORR with ICPi stays in the range of 3% to 12%. [13] [14] [15] 27 Similarly, patients with MET exon 14 altered NSCLC treated with ICPi only have an ORR of 6.7% and a median PFS of 2.3 months (95% CI 1.8-NA). 25 Neversmoking status, low TMB, and a low level of PD-L1 expression in the majority of tumors with a targetable driver may explain the low efficacy of ICPi. 24, 25 In contrast, in our cohort, ICPi therapy was associated with an ORR of 25% to 33% and a median PFS of 3.7 to 4.1 months, which is comparable to the results observed in the second-line setting in the unselected population of NSCLC patients (ORR of 15% to 20% and median PFS of 2.3 to 4 months). [13] [14] [15] This finding might reflect a higher proportion of smokers and a relatively higher TMB in BRAF mutant NSCLC as compared to tumors harboring alterations in the EGFR, ALK, or ROS-1 genes.
Similar ORR, depth of response, and PFS were observed in BRAF V600E mutant and BRAF non-V600E mutant tumors. More importantly, no significant correlation was observed between the PD-L1 expression level and the probability or depth of response. The level of PD-L1 expression did not affect the PFS either. Although tumors with PD-L1 ! 50% were associated with numerically higher ORR and median PFS as compared to tumors with PD-L1 0% to 49%, these differences were not statistically significant. At the time of the analysis, survival since initiation of ICPi was immature; again, neither BRAF mutation type nor the PD-L1 expression level affected OS thus far. Overall, our data is comparable to the results observed in the unselected population of NSCLC patients, aside from the lack of correlation with PD-L1 expression. [13] [14] [15] The lack of correlation between the PD-L1 status and efficacy of ICPi may or may not reflect the small size of the cohort. Because a high level of PD-L1 expression was associated with hyperprogression in two patients, we believe it represents the true finding.
Importantly, a positive correlation was observed between the ICPi exposure and OS. However, imbalances between the ICPi-treated and ICPi-untreated groups in terms of baseline characteristics (ECOG PS status, PD-L1 expression, and TMB) and number of systemic treatment lines -all in favor of the group exposed to ICPi -limit the value of the observation. Additionally, at the time of the analysis, survival was immature for patients who received ICPi. Co-expressing tumors (BRAF V600E mutant tumors with PD-L1 expression in ! 50% of cancer cells) represent an interesting subgroup in which knowing the outcomes with ICPi and targeted therapy is essential in planning first-line systemic treatment. We have attempted to assess and compare the efficacy of these two. The results we obtained thus far were in favor of the combination of BRAF inhibitor þ MEK inhibitor. Importantly, two of six co-expressing tumors have shown a hyperprogression with ICPi. However, the small number of such cases in our series precludes firm conclusions to be drawn with regards to comparative efficacy of ICPi and targeted therapy in this subgroup.
Our study had several limitations. First, absence of a routine BRAF testing for all NSCLC patients may have introduced selection bias. Second, PD-L1 testing was only performed in 74% of patients, and TMB and MSI status was only assessed in approximately 30%. Only 56% of patients were treated with ICPi. The absence of central radiological review along with the absence of uniform intervals for tumor response assessment introduces further uncertainties into the efficacy results of ICPi. Again, imbalances in the baseline characteristics and number of systemic treatment lines limit the conclusions regarding the ICPi impact on OS. Overall, due to its retrospective nature and small number of patients included, the results are only hypothesis generating, and must be validated in a larger prospectively generated cohort.
We can conclude that BRAF mutant NSCLC is associated with a high level of PD-L1 expression, low/ intermediate TMB, and MS-Stable status. ICPi have favorable activity both in BRAF V600E and BRAF non-V600E mutant tumors. A high level of PD-L1 expression in BRAF mutant NSCLC cannot serve as a reliable predictive biomarker for ICPi, especially in the case of BRAF V600E co-expressing tumors; however, more research on the topic is needed.
